Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention

American Journal of Cardiology

Volumn 92, Issue 9, 2003, Pages 1080-1083

  Wolfram, Roswitha ^a   Leborgne, Laurent ^a   Cheneau, Edouard ^a   Pinnow, Ellen E ^a   Canos, Daniel A ^a   Hellinga, David ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Kent, Kenneth M ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CREATINE KINASE MB; EPTIFIBATIDE; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN SECRETION; RETROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0142227659     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.06.004     Document Type: Article

References (20)

1. Kong T.Q.J., Davidson C.J., Meyers S.N., Tauke J.T., Parker M.A., Bonow R.O. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 277:1997;461-466.
2. Stone G.W., Mehran R., Dangas G., Lansky A.J., Kornowski R., Leon M.B. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention a device-specific analysis of 7147 patients. Circulation. 104:2001;642-647.
3. Young E., Prins M., Levine M.N., Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 67:1992;639-643.
4. Hirsh J., Raschke R., Warkentin T.E., Dalen J.E., Deykin D., Poller L. Heparin mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 108:(suppl 4):1995;258S-275S.
5. Hirsh J. Heparin. N Engl J Med. 324:1991;1565-1574.
6. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
7. Bittl J.A., Chaitman B.R., Feit F., Kimball W., Topol E.J. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 142:2001;952-959.
8. Bittl J.A. Bivalirudin for percutaneous coronary interventions development perspective. J Invasive Cardiol. 12:(suppl):2000;2F-6F.
9. Sherman C.T., Litvack F., Grundfest W., Lee M., Hickey A., Chaux A., Kass R., Blanche C., Matloff J., Morgenstern L. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 315:1986;913-919.
10. Falk E. Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 71:1985;699-708.
11. Weitz J.I., Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin- independent inhibitors. Circulation. 17:1998;544-552. 97.
12. Weitz J.I., Buller H.R. Direct thrombin inhibitors in acute coronary syndromes present and future. Circulation. 105:2002;1004-1011.
13. Adgey A.A. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J. 19:(suppl D):1998;D10-21.
14. Scarborough R.M. Development of eptifibatide. Am Heart J. 138:1999;1093-1094.
15. Blankenship J.C., Sigmon K.N., Pieper K.S., O'Shea C., Tardiff B.E., Tcheng J.E. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. Am J Cardiol. 88:2001;969-973.
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
18. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 352:1998;87-92.
19. O'Shea J.C., Hafley G.E., Greenberg S., Hasselblad V., Lorenz T.J., Kitt M.M., Strony J., Tcheng J.E. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention the ESPRIT trial: a randomized controlled trial. JAMA. 285:2001;2468-2473.
20. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 Randomized Trial. JAMA. 289:2003;853-863.